Michail_Petrov-96 Approximately 30% of people who took the GLP-1 weight-loss drugs Saxenda and Wegovy between 2014 and 2023 discontinued them within four weeks of use, according to a new study by Blue Cross Blue Shield. The study analyzed GLP-1 pharmacy and medical claims data amongst its members and also found that 58% discontinued use within 12 weeks. The health insurer said patients generally need to take the drugs for at least 12 weeks to achieve meaningful weight loss that would positively impact their health.
Unpleasant side effects are believed to be a top reason for discontinuing use, with Blue Cross Blue Shield noting that “almost all” new users of the drugs experience gastrointestinal side effects that can include nausea, vomiting and diarrhea. “Because the dose of the drug is increased at regular intervals, this drop-out challenge is common, unless effective coping strategies are identified and discussed with patients before treatment starts,” Blue Cross Blue Shield said in its report. “For patients treated with GLP-1s, side effect can be a considerable treatment persistence challenge.
” Out-of-pocket costs also appear to be a factor, with individuals paying less than $60 a month more likely to stay on their medication than those paying between $60 and $99. Interestingly, those paying over $100 per month were more likely to persist with treatment than those paying $60 to $99, “which may be attributable to motivation related to substantial monetary inve.
